Akira Yoshimoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Akira Yoshimoto has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Ryunosuke Ohkawa
Clinical Bioanalysis and Molecular Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan
6 shared publications - Nobuharu Suzuki
Graduate School of Medical and Dental Sciences, Institute of Science Tokyo/Tokyo Medical and Dental University (TMDU)
2 shared publications - Rina Kawaguchi
Clinical Bioanalysis and Molecular Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
2 shared publications - Takahiro Kameda
Clinical Bioanalysis and Molecular Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
2 shared publications - Tsunehiro Miyakoshi
Department of Clinical Bioanalysis and Molecular Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan
2 shared publications - Azusa Yamazaki
Clinical Bioanalysis and Molecular Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
1 shared publication
Latest Publications
- Open Access
The Maintenance of Dysmyelinated Small‐Diameter Axons by 14‐3‐3s in the Central Nervous System
In the central nervous system, myelin formed around nerve axons by oligodendrocyte enables efficient conduction of action potentials and maintains axonal homeostasis. Therefore, in demyelinating diseases, such as multiple sclerosis (MS), axonal degeneration and loss, particularly in small‐diameter axons, are observed. Teneurin‐4 deficient (Ten‐4 ‐/‐) mice exhibit severe dysmyelination of small‐diameter axons, but survive for over a year. Here, we aimed to elucidate the mechanism of the survival of small‐diameter axons without myelin using Ten‐4 ‐/‐ mice. An immunohistochemical analysis showed abnormally diffused and intense staining of neurofilament. Further, the immunohistochemical signal of nonphosphorylated neurofilament and amyloid precursor protein was higher in Ten‐4 ‐/‐ mice. An electron microscopy analysis unexpectedly revealed that small‐diameter axons in Ten‐4 ‐/‐ mice survived at the age of 1 year, despite the absence of compact myelin. To elucidate the molecular mechanism, we performed a proteomics analysis in the Ten‐4 ‐/‐ tissue by mass spectrometry. The result indicated that four of the seven 14‐3‐3 isoforms were highly expressed in Ten‐4 ‐/‐ small‐diameter axons. Finally, when the function of 14‐3‐3s in Ten‐4 ‐/‐ mice was inhibited by 14‐3‐3 inhibitors, BV02 and difopein, the progression of small‐diameter axon damage was observed. Altogether, 14‐3‐3s are among the pro‐survival factors in dysmyelinated small‐diameter axons. Our findings may be useful for better understanding the pathogenesis of demyelinating diseases, such as MS, as well as for the development of new treatments.
Open AccessThe Maintenance of Dysmyelinated Small‐Diameter Axons by 14‐3‐3s in the Central Nervous System
In the central nervous system, myelin formed around nerve axons by oligodendrocyte enables efficient conduction of action potentials and maintains axonal homeostasis. Therefore, in demyelinating diseases, such as multiple sclerosis (MS), axonal degeneration and loss, particularly in small‐diameter axons, are observed. Teneurin‐4 deficient (Ten‐4 ‐/‐) mice exhibit severe dysmyelination of small‐diameter axons, but survive for over a year. Here, we aimed to elucidate the mechanism of the survival of small‐diameter axons without myelin using Ten‐4 ‐/‐ mice. An immunohistochemical analysis showed abnormally diffused and intense staining of neurofilament. Further, the immunohistochemical signal of nonphosphorylated neurofilament and amyloid precursor protein was higher in Ten‐4 ‐/‐ mice. An electron microscopy analysis unexpectedly revealed that small‐diameter axons in Ten‐4 ‐/‐ mice survived at the age of 1 year, despite the absence of compact myelin. To elucidate the molecular mechanism, we performed a proteomics analysis in the Ten‐4 ‐/‐ tissue by mass spectrometry. The result indicated that four of the seven 14‐3‐3 isoforms were highly expressed in Ten‐4 ‐/‐ small‐diameter axons. Finally, when the function of 14‐3‐3s in Ten‐4 ‐/‐ mice was inhibited by 14‐3‐3 inhibitors, BV02 and difopein, the progression of small‐diameter axon damage was observed. Altogether, 14‐3‐3s are among the pro‐survival factors in dysmyelinated small‐diameter axons. Our findings may be useful for better understanding the pathogenesis of demyelinating diseases, such as MS, as well as for the development of new treatments.
- 31 March 2026
- Published by Elsevier in Sleep Medicine
- Vol. 143, 108936
Synergy effects between cholesterol efflux capacity and CPAP on atherosclerotic coronary plaques in patients with sleep-disordered breathing; the ENTERPRISE-CEC trial
- 31 March 2026
- Published by Elsevier in Sleep Medicine
- Vol. 143, 108936
Synergy effects between cholesterol efflux capacity and CPAP on atherosclerotic coronary plaques in patients with sleep-disordered breathing; the ENTERPRISE-CEC trial
- Open Access
- 21 January 2026
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 46 (1)
Homocysteine thiolactone affects paraoxonase 1 activity via altered paraoxonase 1 distribution on high-density lipoprotein particles
Hyperhomocysteinemia is a risk factor of cardiovascular disease (CVD). High-density lipoprotein (HDL) plays an important role in anti-atherosclerosis, with its anti-atherogenic function attributed to HDL-associated proteins such as apolipoprotein A-I (apoA-I) and paraoxonase 1 (PON1). Homocysteine (Hcy) thiolactone modifies lysine residues in proteins, thereby altering their function. Although dysfunction of apoA-I and PON1 has been reported, the precise modification sites and underlying mechanisms have remained unclear. In this study, we aimed to identify Hcy-thiolactone modification sites on apoA-I and PON1. In addition, we sought to clarify the effects of Hcy-thiolactone on PON1 activity and its distribution. Modification sites were analyzed using MALDI-TOF MS. The effects of Hcy-thiolactone on various specimens, including purified proteins, reconstituted HDL (rHDL), HDL collected by ultracentrifugation, and serum samples, were characterized using enzymatic assays measuring three major PON1 activities (arylesterase, paraoxonase, and lactonase) and Western blotting. Our results demonstrated that while some Hcy-thiolactone modification sites were detected on apoA-I, PON1 itself was not directly modified by Hcy-thiolactone. Thiolactonase activity was reduced by Hcy-thiolactone in large HDL particles. Furthermore, a general reduction of PON1 activity and changes in HDL remodeling and distribution were observed in serum samples treated with Hcy-thiolactone. These findings suggest that PON1 dysfunction induced by Hcy-thiolactone is influenced by alterations in HDL remodeling and the enzyme’s distribution on HDL particles. Analysis of PON1’s distribution dynamics under pathological conditions may provide crucial insights into the mechanism of HDL function decline in CVD.
- 21 January 2026
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 46 (1)
Open AccessHomocysteine thiolactone affects paraoxonase 1 activity via altered paraoxonase 1 distribution on high-density lipoprotein particles
Hyperhomocysteinemia is a risk factor of cardiovascular disease (CVD). High-density lipoprotein (HDL) plays an important role in anti-atherosclerosis, with its anti-atherogenic function attributed to HDL-associated proteins such as apolipoprotein A-I (apoA-I) and paraoxonase 1 (PON1). Homocysteine (Hcy) thiolactone modifies lysine residues in proteins, thereby altering their function. Although dysfunction of apoA-I and PON1 has been reported, the precise modification sites and underlying mechanisms have remained unclear. In this study, we aimed to identify Hcy-thiolactone modification sites on apoA-I and PON1. In addition, we sought to clarify the effects of Hcy-thiolactone on PON1 activity and its distribution. Modification sites were analyzed using MALDI-TOF MS. The effects of Hcy-thiolactone on various specimens, including purified proteins, reconstituted HDL (rHDL), HDL collected by ultracentrifugation, and serum samples, were characterized using enzymatic assays measuring three major PON1 activities (arylesterase, paraoxonase, and lactonase) and Western blotting. Our results demonstrated that while some Hcy-thiolactone modification sites were detected on apoA-I, PON1 itself was not directly modified by Hcy-thiolactone. Thiolactonase activity was reduced by Hcy-thiolactone in large HDL particles. Furthermore, a general reduction of PON1 activity and changes in HDL remodeling and distribution were observed in serum samples treated with Hcy-thiolactone. These findings suggest that PON1 dysfunction induced by Hcy-thiolactone is influenced by alterations in HDL remodeling and the enzyme’s distribution on HDL particles. Analysis of PON1’s distribution dynamics under pathological conditions may provide crucial insights into the mechanism of HDL function decline in CVD.
- Open Access
- 23 September 2025
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 44, 102274
Usefulness of plasma and apolipoprotein B-depleted serum samples in paraoxonase 1 assessment
- 23 September 2025
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 44, 102274
Open AccessUsefulness of plasma and apolipoprotein B-depleted serum samples in paraoxonase 1 assessment
- Open Access
- 17 September 2025
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 44, 102264
Metformin interferes with urinary creatinine measurement using enzymatic method
- 17 September 2025
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 44, 102264
Open AccessMetformin interferes with urinary creatinine measurement using enzymatic method
- Open Access
- 17 July 2025
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 45 (07) , 415-427
Development and validation of direct assay for cholesterol content of erythrocytes
Erythrocytes contain a significant amount of membrane cholesterol, which is continuously exchanged with lipoproteins. Recent studies suggest that erythrocyte cholesterol content correlates positively with atherosclerotic cardiovascular disease (ASCVD) severity independent of low-density lipoprotein levels, potentially reflecting residual ASCVD risk. However, conventional methods for measuring erythrocyte cholesterol content require labor-intensive lipid extraction procedures, limiting their clinical applicability. In this study, we developed a novel enzymatic assay that enables direct quantification of erythrocyte total cholesterol content using two denaturants to eliminate hemoglobin interference. This simple method demonstrated high accuracy and precision, as confirmed by intra-assay repeatability, between-day precision, linearity, and spike-recovery tests. Using this assay, we determined the erythrocyte cholesterol content per volume (154.8 ± 2.9 mg/dl in men, 155.9 ± 6.9 mg/dl in women) and per cell (139.0 ± 5.2 fg/cell in men, 140.8 ± 5.3 fg/cell in women) (n = 12, healthy subjects). While erythrocyte cholesterol content per volume correlated with the conventional method, the erythrocyte cholesterol content per cell showed no such correlation. Moreover, neither measure was associated with serum lipid levels, suggesting their potential as independent biomarkers for ASCVD. Additionally, we evaluated erythrocyte cholesterol content across different maturation stages and found that older erythrocytes had significantly lower cholesterol content, consistent with mass spectrometry results. These findings further validated the physiological relevance of the proposed method. In conclusion, we successfully established a simple and clinically applicable enzymatic method for measuring erythrocyte cholesterol content, providing novel insights into erythrocyte cholesterol metabolism and its potential role in ASCVD risk assessment.
- 17 July 2025
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 45 (07) , 415-427
Open AccessDevelopment and validation of direct assay for cholesterol content of erythrocytes
Erythrocytes contain a significant amount of membrane cholesterol, which is continuously exchanged with lipoproteins. Recent studies suggest that erythrocyte cholesterol content correlates positively with atherosclerotic cardiovascular disease (ASCVD) severity independent of low-density lipoprotein levels, potentially reflecting residual ASCVD risk. However, conventional methods for measuring erythrocyte cholesterol content require labor-intensive lipid extraction procedures, limiting their clinical applicability. In this study, we developed a novel enzymatic assay that enables direct quantification of erythrocyte total cholesterol content using two denaturants to eliminate hemoglobin interference. This simple method demonstrated high accuracy and precision, as confirmed by intra-assay repeatability, between-day precision, linearity, and spike-recovery tests. Using this assay, we determined the erythrocyte cholesterol content per volume (154.8 ± 2.9 mg/dl in men, 155.9 ± 6.9 mg/dl in women) and per cell (139.0 ± 5.2 fg/cell in men, 140.8 ± 5.3 fg/cell in women) (n = 12, healthy subjects). While erythrocyte cholesterol content per volume correlated with the conventional method, the erythrocyte cholesterol content per cell showed no such correlation. Moreover, neither measure was associated with serum lipid levels, suggesting their potential as independent biomarkers for ASCVD. Additionally, we evaluated erythrocyte cholesterol content across different maturation stages and found that older erythrocytes had significantly lower cholesterol content, consistent with mass spectrometry results. These findings further validated the physiological relevance of the proposed method. In conclusion, we successfully established a simple and clinically applicable enzymatic method for measuring erythrocyte cholesterol content, providing novel insights into erythrocyte cholesterol metabolism and its potential role in ASCVD risk assessment.